
By leveraging high-throughput sequencing technology and placing liquid biopsy at its core, HaploX offers a comprehensive range of clinical genetic testing solutions tailored to solid tumors, encompassing the entire cancer management cycle based on clinical requirements.

Pan-Cancer Genetic Testing Assays
Minimal Residual Disease (MRD) Detection Assays



Specific-Cancer Genetic Testing Assays

Lung Cancer

Gynecologic Cancer

Hepatobiliary and Pancreatic Cancer

Gastrointestinal Cancer

Breast Cancer

Urological Cancer

Central Nervous System Tumors
Raw Data
Comprehensive
and Fast
Professional Interpretation
Anti-counterfeiting
Report
Self-developed Algorithms
Top-notch Quality
Control



